Hepatitis/MASH

Lawsuits challenge access denials to curative hepatitis C drugs among incarcerated individuals infected with the disease.

Liver disease experts suggest how to prioritize the treatment of different HCV patient groups.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

The once daily oral medication is for use with Sovaldi with or without ribavirin or in combination with peginterferon alfa and ribavirin.

Once-daily combination would be the first all-oral, pan-genotypic single tablet for treatment of HCV.

The FDA is reviewing Gilead Sciences' new drug application (NDA) for a fixed dose combination of sofosbuvir (Solvadi) and velpatasvir to treat genotype 1-6 hepatitis C virus infection.

Hepatic decompensation and liver failure in patients with underlying liver cirrhosis more common with drug regimen.

Many RA treatments suppress the immune system, leaving patients at risk for contracting a potentially fatal infection.

Panel discusses treatment barriers during annual NASP conference.

Immune mechanisms found to have significant impact on overcoming HCV.

Pan-virals show potential to work across all HCV genotypes.

Injection drug use most frequently linked to a positive hepatitis C screening.

Chronic hepatitis C infection linked to the prevalence of plaque and noncalcified plaque in the arteries.

Targeted drug delivery focuses on diseased cells to minimize side effects on normal cells.

Expansion addresses patients co-infected with HIV, patients with advanced cirrhosis, and patients with post-liver transplant HCV recurrence.

The FDA is considering expanding the use for a drug currently indicated as a chronic hepatitis C (HCV) treatment.

Ex-vivo lung perfusion keeps the lung alive, breathing outside the body and supported by a supply of blood and nutrients.

Hepatitis C infections are more likely to become persistent and to lead to progressive liver disease in patients with HIV.

Hepatic inflammation and metabolic factors associated with hepatosteatosis in patients with chronic hepatitis C infection.

Velpatasvir is a pangenotypic NS5A inhibitor for patients with hepatitis C genotypes 1 through 6 of the virus.

For patients with hepatitis C seeking modern treatment options, many health plans force health care professionals use criteria that are clinically unsound.